

## *Table of Contents*

---

<b>AVAC's New Scope—and Enduring Commitment: A letter from the Executive Director</b>	<b>3</b>
Our Guiding Principles	6
<b>Executive Summary</b>	<b>7</b>
<b>Key Recommendations</b>	<b>8</b>
<b>AVAC's Status Report—An Update on Last Year's Recommendations</b>	<b>9</b>
<b>SECTION 1: New Countdowns</b>	<b>11</b>
<b>More Than Money: What the Field Needs Now</b>	<b>13</b>
Moving Beyond Pipelines	19
Today's Trial Landscape: Not as Simple as I, II, III	20
<b>The 2007 AVAC Industry Survey</b>	<b>21</b>
<b>A Call to Action for the Global HIV Vaccine Enterprise</b>	<b>25</b>
<b>SECTION 2: Racing Against Time</b>	<b>31</b>
<b>Building Global Approaches on Local Experiences</b>	<b>33</b>
Engaging African Americans in HIV-Prevention Research: 17 Percent is Not Good Enough	35
Shifting Standard of Prevention and Clinical Trial Capacity: Forecasting the Future	37
<b>New NIH Funding Structures: The Jury is Out</b>	<b>39</b>
Not There Yet: A Call for Global Consensus on Standard of Prevention and Level of Care	41
WANTED: Input on Good Participatory Practice Guidelines	43
<b>SECTION 3: Wake Up Call</b>	<b>47</b>
<b>Caution and Curiosity: Why Aren't We Striking the Balance When it Comes to New Prevention Tools?</b>	<b>49</b>
HPV Vaccine: Worrying Delays and Challenges to Rollout	54
Comprehensive HIV Prevention: Turning Our Favorite Rhetoric Into Reality	56
<b>Exploring Responses to Today's New Prevention Interventions</b>	<b>57</b>
<b>About AVAC</b>	<b>61</b>
<b>LIST OF FIGURES, TABLES AND ILLUSTRATIONS</b>	
Figure 1. Global Coverage for Select HIV Prevention Strategies in 2005	4
Figure 2. Global HIV Incidence With and Without Comprehensive Prevention Package	5
Figure 3. Public, Philanthropic and Commercial Funding for HIV Vaccines in 2006	14
Figure 4. Shrinking Percentage of NIH Vaccine Funds for Investigator-initiated Research	14
Figure 5. Projecting the NIH Budget: 3.7% Biomedical Inflation Plus 0%, 5%, and 10% Annual Increases from 2008-13	15
Figure 6. Consolidating Funds for "Big Science"—the NIH Example	15
Figure 7. Anticipated Data Milestones and Proposed Needs for the Future	16
Figure 8. Non-commercial Funding Allocations for Preventive HIV Vaccine R&D by Category in 2000-06	17
Table 1. Test-of-Concept Versus Phase III: A Comparison	18
Table 2. Commercial Engagement in Preventive HIV Vaccine R&D by Company In 2006	22
Table 3. Industry HIV Vaccine Involvement 2007	23
Figure 9. Global HIV Vaccine Enterprise Timeline 2003-07	27
Illustration: HIV Prevention Roadmap	30
Figure 10. Total Investments (2001-07) in Research on Male Circumcision for HIV Prevention	34
Figure 11. Countries with AIDS Vaccine Trials (August 2007)	39
Table 4. Trials of New Prevention Options Worldwide	42
Table 5. Trials of Preventive HIV/AIDS Vaccines Worldwide (August 2007)	44-45
Figure 12. Coverage of Essential Prevention Services	51
Figure 13. HIV Prevention Research: A Comprehensive Timeline of Efficacy Trials	52-53